Reaction
Cancer Surgery reporting signals
As of the last recalculation, Cancer Surgery appears in 944 FAERS reports alongside 17 co-occurring drug terms. The strongest observed disproportionality signal is PANITUMUMAB (PRR 27.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Panitumumab | 19 | 27.3 | 27.3 |
| Entecavir | 11 | 21.0 | 21.0 |
| Bimekizumab | 19 | 20.1 | 20.1 |
| Pembrolizumab | 47 | 10.3 | 10.3 |
| Fluticasone Propionate And Salmeterol | 19 | 10.2 | 10.2 |
| Niraparib | 10 | 10.0 | 10.0 |
| Abatacept | 59 | 10.0 | 10.0 |
| Cetuximab | 13 | 9.3 | 9.3 |
| Ranolazine | 4 | 8.5 | 8.5 |
| Ivacaftor | 3 | 8.4 | 8.4 |
| Vismodegib | 3 | 7.5 | 7.5 |
| Liraglutide | 15 | 6.8 | 6.8 |
| Encorafenib | 3 | 6.7 | 6.7 |
| Certolizumab Pegol | 34 | 6.6 | 6.6 |
| Patiromer | 3 | 4.8 | 4.8 |
| Alirocumab | 5 | 4.4 | 4.4 |
| Pimavanserin Tartrate | 8 | 3.2 | 3.2 |